

August 6, 1968

Dr. Lee Gordon
Hoffmann-La Roche, Inc.
Nutley, New Jersey 07110

Dear Dr. Gordon:

Mr. Weisman was kind enough to approach us regarding a high dose Librium study. As you may recognize such a study does not stimulate much interest in the treating physicians since they have already accepted high doses as a standard. As this has been the first study that Hoffmann-La Roche has recommended, I regret that we are unable to carry it out.

Some years ago I undertook phase 3 and phase 4 clinical evaluation studies at Hillside Hospital. While in Missouri I found phase 2 and late phase 1 studies of greater interest and developed, in conjunction with my associates, Drs. Itil and Shapiro, a method of EEG analysis which we feel contributes to our understanding of the mode of action and target populations for new psychoactive drugs. I am taking the liberty of enclosing a copy of a review of EEG and drug effects which I prepared for the ACNP in 1967.

We are particularly interested in phase 2 and late phase 1 studies, especially those which permit us to utilize our EEG model. The facilities for new drug evaluation in this Department are extensive and include two EEG laboratories and a computer facility, a 25 bed in-patient unit for narcotic addicts and psychotic patients, a large mental health clinic servicing a wide variety of populations, and lately a special out-patient unit for children and adolescents. It might be useful for you or some of your associates to visit our facilities in order to obtain an appreciation of the opportunities which they represent.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp

cc: Mr. H. Weisman